fruquintinib
hutchmed
['fruquintinib', 'rectal', 'colorectal']
fruquintinib, a tyrosine kinase inhibitor, improved overall survival by 2.6 months in refractory metastatic #colorectalcancer, according to data reported at #esmo22. 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.